Table 1.
Geometric mean concentrations and fold rises in the levels of antigen-specific IFN-γ and granzyme B in vaccinated subjects before and after vaccination, and percentage of subjects with ≥1.5-fold increase in IFN-γ and granzyme B levels after vaccination: (a) GMCs and GMCFRs upon the stimulation of whole blood with vaccine antigens; (b) percentage of subjects with ≥1.5-fold increase in IFN-γ and granzyme B levels upon vaccination.
| (a) | ||||||||||
| n = 32 | IFN- γ : GMC (GMCFR) | Granzyme B: GMC (GMCFR) | ||||||||
| Pre-vaccine | 2 wks | 5 mos | Pre-vaccine | 2 wks | 5 mos | |||||
| H1N1 | 429.9 | 801.1 (1.9) | 307.5 (0.72) | 76.3 | 173.2 (2.3) | 53.9 (0.71) | ||||
| H3N2 | 344.8 | 597.4 (1.7) | 218.5 (0.6) | 68.9 | 122.7 (1.8) | 34.4 (0.5) | ||||
| Yamagata lineage | 490 | 835.1 (1.7) | 349 (0.7) | 87 | 196.8 (2.3) | 79.3 (0.9) | ||||
| Victoria lineage | 531.5 | 909.7 (1.7) | 350 (0.66) | 87.7 | 187 (2.1) | 66 (0.75) | ||||
| (b) | ||||||||||
| IFN- γ | Granzyme B | |||||||||
| n = 32 | 2 wks | 5 mos | 2 wks | 5 mos | ||||||
| H1N1 | 50% (16/32) | 25% (8/32) | 56.3% (18/32) | 28% (9/32) | ||||||
| H3N2 | 50% (16/32) | 22% (7/32) | 43.8% (14/32) | 16% (5/32) | ||||||
| Yamagata lineage | 50% (16/32) | 22% (7/32) | 62.5% (20/32) | 28% (9/32) | ||||||
| Victoria lineage | 62.5% (20/32) | 19% (6/32) | 65.6% (21/32) | 28% (9/32) | ||||||
GMC—geometric mean concentration; GMCFR—geometric mean fold rise; 2 wks—two weeks post-vaccination; 5 mos—five months post-vaccination. 2 wks—two weeks post-vaccination; 5 mos—five months post-vaccination.